Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14463964 | 1.00 | KMT2A (0.38) | KMT2AABL1RIN1TDP1PTGER4 | |
| SCHEMBL5214704 | 1.00 | KMT2A (0.38) | KMT2AABL1RIN1TDP1PTGER4 | |
| SCHEMBL5214696 | 1.00 | KMT2A (0.38) | KMT2AABL1RIN1TDP1PTGER4 | |
| SCHEMBL5213009 | 0.85 | KMT2A (0.37) | KMT2AABL1RIN1TDP1TSHR | |
| SCHEMBL5213001 | 0.85 | KMT2A (0.37) | KMT2AABL1RIN1TDP1TSHR | |
| SCHEMBL5215716 | 0.85 | KMT2A (0.37) | KMT2AABL1RIN1TDP1TSHR | |
| SCHEMBL5215685 | 0.83 | PTGER4 (0.41) | PTGER4POLB | |
| SCHEMBL5215677 | 0.83 | PTGER4 (0.41) | PTGER4POLB | |
| SCHEMBL5215669 | 0.83 | PTGER4 (0.41) | PTGER4POLB | |
| SCHEMBL5216829 | 0.81 | PTGER4 (0.59) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1408961-B1 | 2 PYRROLIDONE DERIVATIVES AS PROSTANOID AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-6849657-B2 | 2-pyrrolidone derivatives as prostanoid agonists | SYNTEX (U.S.A.) LLC (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030064964-A1 | 2-pyrrolidone derivatives as prostanoid agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064964-A1 | 2-pyrrolidone derivatives as prostanoid agonists | PTGER1, PTGER4, PTGIR | KMT2A 1519/4885ABL1 2662/4885RIN1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.